शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ENTERONSEEntero Healthcare Solutions Limited· RetailingHighPositive
Announced Wed, 12 Nov, 2025 · 19:23 IST

Entero to acquire 80% in Bioaide and 51% in Anand Chemiceutics

Listed-company acquisitionStrategic Transactions View source PDFExplain this filing

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.9%Reaction day
₹1136.50
prior close
₹1156.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%+1.0% vs market
Retailing peers, median of 57sector · industry level-0.9%+1.8% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.8 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.2
10m
-1.9
15m
-1.9
30m
-2.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.9-0.1+1.0-0.9+1.8
Next day
-0.3-0.2-0.1-0.9+0.6
2d
+0.3+0.4-0.1-0.7+1.0
3d
-0.4-0.4-0.0-1.3+0.9
4d
-4.3-0.6-3.7-1.3-3.0
5d
-5.9-0.9-5.0-2.0-3.8
1w
-7.4-3.0-4.4-3.7-3.8
15d
-8.5-3.9-4.6-5.3-3.2
1m
-11.6-4.8-6.8-5.4-6.2
2m
+7.4-7.8+15.2-8.8+16.2
3m
+0.4-7.2+7.6-12.4+12.8
UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 57Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved acquiring 80% stake in Bioaide Technologies (Delhi) for INR 31.13 to 36 Crore in cash, to close by Feb 15, 2026. Also approved 51% stake in Anand Chemiceutics (Pune) for INR 210 to 230 Crore cash via slump sale, subject to due diligence. Both firms distribute medical devices, aligning with Entero's core business. Bioaide FY25 revenue about INR 55.8 Crore; Anand group FY25 revenue about INR 474.9 Crore.

Likely market impact

Two bolt-on acquisitions strengthen Entero's medical device distribution network. Combined cost up to about INR 266 Crore in cash, likely funded internally.